Argenx Se (ARGX) Short-term Investments (2015 - 2026)
Argenx Se's (ARGX) quarterly Short-term Investments came in at $1.6 billion in Q2 2026, down 99.86% YoY from $1154.3 billion in Q2 2025, and up 68.6% on a QoQ basis from $949.0 million in Q4 2025.
Argenx Se (ARGX) Short-term Investments (2015 - 2026) Analysis & Trends
Argenx Se (ARGX) has 12 years of Short-term Investments data on file, last reported at $1.6 billion in Q2 2026.
- Quarterly Short-term Investments fell 99.86% year-over-year to $1.6 billion in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $1.6 billion (down 99.86% YoY) and the FY2025 annual result came in at $2.4 billion, up 209.38% from the prior year.
- Short-term Investments climbed to $1.6 billion in Q2 2026, from $949.0 million in the prior quarter.
- In the past five years, Short-term Investments ranged from a high of $1154.3 billion in Q2 2025 to a low of -$1108.4 billion in Q2 2024.
- A 5-year average of $6.1 billion and a median of $1.2 billion in 2022 frame the typical range for Short-term Investments.
- Annual changes were most pronounced in 2024 — Short-term Investments plunged 125146.11% — and 2025, when it surged 204.14%.
- Tracing ARGX's Short-term Investments over 5 years: stood at $1.4 billion in 2022, then declined by 18.74% to $1.1 billion in 2023, then jumped by 66.13% to $1.9 billion in 2024, then sank by 49.49% to $949.0 million in 2025, then surged by 68.6% to $1.6 billion in 2026.
- The last three Short-term Investments figures came in at $1.6 billion (Q2 2026), $949.0 million (Q4 2025), and $1154.3 billion (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.60 Bn |
| Dec 31, 2025 | 949.00 Mn |
| Jun 30, 2025 | 1,154.26 Bn |
| Dec 31, 2024 | 1.88 Bn |
| Jun 30, 2024 | -1,108.41 Bn |
| Dec 31, 2023 | 1.13 Bn |
| Jun 30, 2023 | 886.40 Mn |
| Dec 31, 2022 | 1.39 Bn |
| Jun 30, 2022 | 1.23 Bn |
| Dec 31, 2021 | 1.00 Bn |
| Jun 30, 2021 | 1.15 Bn |
| Dec 31, 2020 | 757.53 Mn |
| Jun 30, 2020 | 805.56 Mn |
| Dec 31, 2019 | 1.11 Bn |
| Jun 30, 2019 | 872.49 Mn |
| Dec 31, 2018 | 323.62 Mn |
| Jun 30, 2018 | 236.28 Mn |
| Dec 31, 2017 | 198.88 Mn |
| Jun 30, 2017 | 107.64 Mn |
| Dec 31, 2016 | 7.38 Mn |